fatty acid oxidation raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-09-08. Anything still debated is marked as such rather than presented as settled.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 317318-70-0 | Unique identifier for the compound. |
| Chemical class | PPARδ agonist | Synthetic ligand for peroxisome proliferator-activated receptor delta. |
| Appearance | White to off-white solid | Typical form of research-grade material. |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water. |
| Typical storage | -20°C | Recommended for long-term storage of stock solutions. |
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
The industry was expected to invest US$7.1 billion in integrated resorts (US$3.5 billion in Marina Bay; US$3.6 billion in Resorts World). In 2008, the CRA was formed to regulate gambling in management and operation of the casinos in Singapore. It was reconstituted to form the GRA in 2022. On 20 July 2017, the Ministry of Home Affairs announced that regulations on slot machines would be tightened over the next two years and included changes that added more stringent criteria to meet for permits, requirements aimed at reducing availability and accessibility, and setting in place social safeguards to mitigate potential problem gambling. In 2018, the newly formed Singapore Premier League (SPL), known previously as S.League, disallowed non-SPL clubs to have slot machines while SPL clubs to have a maximum of 15 machines, by the end of 2019. On 15 September 2022, SPL clubs were informed to stop all jackpot operations by the end of October.
Following the 1971 war with India, Pakistan hastily developed atomic weapons to deter foreign intervention and entered the atomic age. Tensions with India led to Pakistan's 1998 underground nuclear tests, making it the seventh country to possess such weapons. Pakistan is the sole Muslim nation active in Antarctica research, maintaining its Jinnah Antarctic Research Station since 1992. The government invests heavily in information technology projects, focusing on e-government and infrastructure.
=== Pharmacokinetics === Abrocitinib is quickly absorbed from the gut and generally reaches highest blood plasma concentrations within one hour. Only 1.0 to 4.4% of the dose are found unmetabolized in the urine. The half-life of abrocitinib is 5 hours and the absorption is not affected by food. A higher dose (400–800 mg) would delay the absorption to 1.5–4 hours. A steady plasma concentration of abrocitinib can be obtained within 48 hours of treatments. The dose is one daily, and abrocitinib is metabolized mainly by cytochrome P450 (CYP450) in liver such as CYP2C9, CYP2C19, CYP3A4 and CYP2B6. The major metabolites of abrocitinib are pyrrolidinone pyrimidine (inactive), 2-hydroxypropyl (active), and 3-hydroxypropyl (active). Dose reduction to half is advisable when abrocitinib is taken with strong inhibitors of CYP2C19. According to phase 1 clinical trials on abrocitinib oral dose of 200 mg, hepatic functions were not altered. However, it is advisable to reduce the dose by half in case of reduced renal function. In serious hepatic impairment and final stages of renal disease, Abrocitinib is contraindicated. Some changes may occur during the abrocitinib treatment such as the reduction in platelet counts after 4 weeks of starting Abrocitinib. However, they will return to normal at the end of the treatment. An increase in LDL, HDL, and total cholesterol levels was also recorded after 4 weeks of Abrocitinib treatment. The increased levels depend on the abrocitinib dose (15% increase in LDL with 200 mg dose versus 10% increase with 100 mg).
=== Detection of aircraft === In 1931, Arnold Frederic Wilkins joined Watt's staff in Slough. As the "new boy", he was given a variety of menial tasks to complete. One of these was to select a new shortwave receiver for ionospheric studies, a task he undertook with great seriousness. After reading everything available on several units, he selected a model from the General Post Office (GPO) that worked at (for that time) very high frequencies. As part of their tests of this system, in June 1932 the GPO published a report, No. 232 Interference by Aeroplanes. The report recounted the GPO testing team's observation that aircraft flying near the receiver caused the signal to change in intensity, an annoying effect known as fading. The stage was now set for the development of radar in the UK. Using Wilkins' knowledge that shortwave signals bounced off aircraft, a BBC transmitter to light up the sky as in Appleton's experiment, and Watt's RDF technique to measure angles, a complete radar could be built. While such a system could determine the angle to a target, it could not determine its range and provide a location in space. To do so, two such measurements would have to be made from different locations. Watt's huff-duff technique solved the problem of making rapid measurements, but the issue of coordinating the measurement at two stations remained, as did any inaccuracies in measurement or differences in calibration between the two stations.
Sources: en.wikipedia.org
==== MeSH D08.244.453 – cytochrome p-450 enzyme system ==== MeSH D08.244.453.040 – aryl hydrocarbon hydroxylases MeSH D08.244.453.040.050 – aniline hydroxylase MeSH D08.244.453.040.110 – benzopyrene hydroxylase MeSH D08.244.453.040.555 – cytochrome p-450 cyp1a1 MeSH D08.244.453.040.777 – cytochrome p-450 cyp1a2 MeSH D08.244.453.040.888 – cytochrome p-450 cyp2b1 MeSH D08.244.453.040.944 – cytochrome p-450 cyp2d6 MeSH D08.244.453.040.972 – cytochrome p-450 cyp2e1 MeSH D08.244.453.040.986 – cytochrome p-450 cyp3a MeSH D08.244.453.085 – camphor 5-monooxygenase MeSH D08.244.453.915 – steroid hydroxylases MeSH D08.244.453.915.050 – aldosterone synthase MeSH D08.244.453.915.099 – aromatase MeSH D08.244.453.915.200 – cholesterol 7 alpha-hydroxylase MeSH D08.244.453.915.212 – cholesterol side-chain cleavage enzyme MeSH D08.244.453.915.400 – 25-hydroxyvitamin d3 1-alpha-hydroxylase MeSH D08.244.453.915.720 – steroid 11-beta-hydroxylase MeSH D08.244.453.915.730 – steroid 12-alpha-hydroxylase MeSH D08.244.453.915.737 – steroid 16-alpha-hydroxylase MeSH D08.244.453.915.748 – steroid 17-alpha-hydroxylase MeSH D08.244.453.915.760 – steroid 21-hydroxylase MeSH D08.244.453.957 – trans-cinnamate 4-monooxygenase
The dose of 1S-LSD is reported to be similar to that of LSD. Blotter tabs containing 129 μg 1S-LSD have been encountered. 1S-LSD is thought to be a prodrug and produces similar effects as LSD and other LSD prodrugs.
Immune-mediated causes could include transient factors as in Mycoplasma pneumoniae infection (cold agglutinin disease) or permanent factors as in autoimmune diseases like autoimmune hemolytic anemia (itself more common in diseases such as systemic lupus erythematosus, rheumatoid arthritis, Hodgkin's lymphoma, and chronic lymphocytic leukemia). Spur cell hemolytic anemia Any of the causes of hypersplenism (increased activity of the spleen), such as portal hypertension. Acquired hemolytic anemia is also encountered in burns and as a result of certain infections (e.g. malaria). Lead poisoning or poisoning by arsine or stibine causes non-immune hemolytic anemia. Runners can develop hemolytic anemia due to "footstrike hemolysis", the destruction of red blood cells in feet at foot impact. Low-grade hemolytic anemia occurs in 70% of prosthetic heart valve recipients, and severe hemolytic anemia occurs in 3%.
These patterns indicate a metabolically coordinated, multi-partner community of bacteria and other microbes, rather than a simple fungus–alga pair. Lichens are now framed as holobionts—multi-partner units on which selection may act. Taxonomically, however, only the fungal partner is named under the ICN; the holobiont as a whole is not ranked. By convention and by the International Code of Nomenclature (ICN) rules, each lichen is formally referred to by the fungus's name. Consequently, a single fungus can form contrasting "photomorphs" with different photobionts. Historically, photomorphs were often misclassified as separate species or varieties. Many photomorphs were once misdescribed as separate taxa; molecular work on Lecanographa amylacea showed its algal and cyanobacterial forms belong to one fungus. Article F.1.1 (one fungus, one name) mandates a single valid name; informal tags such as "cyanomorph" or "green morph" may be added descriptively. To communicate the difference, lichenologists might append informal qualifiers, such as Lobaria pulmonaria cyanomorph and green morph, but these are not separate taxa. Proposals to rank photomorphs formally (e.g., as formae) gained little traction because the variants reflect ecology, not lineage. In practice, photomorphs are an aspect of intraspecific variability. Situations of optional lichenization (where a fungus can live either as a lichen or independently) complicate matters.
ALK-positive ALCL is diagnosed by histological and immunological examinations of involved tissues, typically lymph nodes. These tissues have lymphoma-like infiltrates that have variable numbers of ALCL "hallmark" cells, i.e. cells with kidney- or horseshoe-shaped nuclei that strongly express CD30 as detected by immunohistochemistry and an ALK fusion protein as detected by fluorescence in situ hybridization. These cells are scattered throughout the infiltrates. WHO classifies these infiltrates into 5 patterns: a common pattern consisting of large variably shaped cells with large nuclei that typically contain multiple nucleoli (60–70% of cases); a small-cell pattern consisting of small to medium-sized neoplastic cells with clear cytoplasm and "hallmark" cells that are concentrated around small blood vessels (5–10% of cases); a lymphohistiocytic pattern consisting of small neoplastic cells along with abundant histiocytes (10% of cases); a Hodgkin's-like pattern in which the architecture resembles the nodular sclerosis pattern of Hodgkin lymphoma (3% of cases); and a composite pattern consisting of two or more of the just described patterns (15% of cases). Detection of circulating autoantibody against ALK supports the diagnosis. Individuals with low levels of these autoantibodies are at an increase risk of relapsing after treatment.
Sources: en.wikipedia.org
Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.
No. Cardarine is not an anabolic steroid; it belongs to a different chemical class that targets PPARδ. Steroids act primarily through androgen receptors, while cardarine acts through a nuclear receptor involved in metabolism.
Some rodent studies reported increased endurance and changes in fat metabolism after cardarine exposure. Long-term studies in animals also raised concerns about cancer in certain tissues. Human trial data are limited, so these findings cannot be directly translated to people.
No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.